Eli Lilly's Stock Climbs After Analyst Upgrades On Optimism Over Diabetes Drug
October 09, 2015 at 09:29 AM EDT
Eli Lilly & Co.'s stock climbed 1.7% in premarket trade Friday, after the drug maker was upgraded at Credit Suisse, which said it anticipated better-than-expected sales of the diabetes drug Jardiance, sooner than originally expected.